Why the study?
Does nebivolol, perindopril, or L-arginine improve nitric oxide production and functional capacity in patients with peripheral occlusive arterial disease?
RCT (n=80)
Open-label
Randomized
No
Does nebivolol, perindopril, or L-arginine improve nitric oxide production and functional capacity in patients with peripheral occlusive arterial disease?
L-arginine, perindopril, and nebivolol significantly increased nitric oxide production and improved pain-free walking distance in patients with peripheral occlusive arterial disease.
Answers are grounded in this paper and cite their sources.
L-arginine may improve walking distance in PAD; extends nitric oxide augmentation as a therapeutic strategy.
No abstract yet. The journal hasn't published one we can show.
No takes yet. Share an insight, caveat, or question.
Швальб et al. (2011) conducted an RCT in Peripheral occlusive arterial disease (n=80). Nebivolol, Perindopril, or L-arginine vs. Standard conservative therapy was evaluated on Nitric oxide (NO) level at 1 month (p=<0.05).
Synapse has enriched 10 related papers. Consider them for comparative context: